Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 17

1155P - Updated results of surufatinib plus transarterial embolization versus surufatinib monotherapy in neuroendocrine tumor with liver metastasis: A prospective, randomized, controlled trial

Date

14 Sep 2024

Session

Poster session 17

Topics

Tumour Site

Neuroendocrine Neoplasms

Presenters

Dan Cao

Citation

Annals of Oncology (2024) 35 (suppl_2): S749-S761. 10.1016/annonc/annonc1598

Authors

D. Cao1, X. Li1, X. You1, R. Li1, J. Xiang2, H. Lan3, J. Wang4, N. Ke5

Author affiliations

  • 1 Department Of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, 610041 - Chengdu/CN
  • 2 Institute Of Hepatopancreatobiliary Surgery, Chongqing General Hospital, Chongqing University, 401147 - Chongqing/CN
  • 3 Oncology Center, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, 610072 - Chengdu/CN
  • 4 Department Of Medical Oncology, Mianyang General Hospital, 621000 - Mianyang/CN
  • 5 Department Of Pancreatic Surgery, West China Hospital, Sichuan University, 610041 - Chengdu/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1155P

Background

The liver is the predominant site for metastases in neuroendocrine tumors (NETs). Surufatinib (SUR), an oral tyrosine kinase inhibitor, is endorsed as a systemic therapeutic standard for advanced NETs. Transarterial embolization (TAE) stands as the principal local intervention for inoperable hepatic metastatic NETs. This study was executed to assess the efficacy and safety of combined surufatinib with TAE versus surufatinib monotherapy in patients with hepatic metastases from NETs.

Methods

This was a prospective, randomized, controlled trial including patients (pts, ≥18 years) with liver metastatic NETs (Grade 1 or 2), and at least one RECIST 1.1-measurable hepatic lesion. A total of up to 123 participants are to be enrolled, all with an ECOG performance status 0 to 2, and an expected survival exceed 12 weeks. Pts were randomly assigned (1:1) to receive SUR (300 mg daily) plus TAE, or SUR alone. The primary endpoint was PFS, with secondary endpoints including intrahepatic response rate (iHRR), ORR, DCR, OS and incidence of adverse events.

Results

As of April 2024, 29 pts were enrolled, with 15 allocated to SUR + TAE group. Primary tumor sites included the pancreas (19/29), duodenum (3/29), stomach (2/29), liver (3/29), rectum (1/29), and appendix (1/29), with a median Ki-67 index of 10% (range: 1-15%). With a median follow-up of 7.9 months, the median PFS and OS were not mature. In 20 evaluable pts, 7 achieved a partial response (PR) and 11 maintained stable disease (SD), while only 2 patient exhibited disease progression (PD). Compared to SUR group, the ORR in SUR + TAE group showed improved tendency (22.2% vs. 45.5%, p=0.279). The DCR reached 100% in the SUR+TAE group, surpassing the 77.8% observed in the SUR group. Median PFS and OS have not yet been attained. The incidence of treatment-related adverse events, such as hypertension, proteinuria, and diarrhea, was similar between groups, with one case of grade 3 proteinuria in each but no grade 4 events.

Conclusions

The combination of surufatinib and TAE shows promising superior efficacy compared to surufatinib monotherapy, heralding a promising therapeutic advance for neuroendocrine tumors with liver metastasis.

Clinical trial identification

ChiCTR2300071991.

Editorial acknowledgement

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.